Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-Moderate Alzheimer's Disease.

Trial Profile

Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 May 2017 Results of a cost analysis presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 09 Dec 2016 According to an Axovant Sciences media release, new analysis of this was presented in an oral session at the 2016 Clinical Trials in Alzheimer's Disease (CTAD) Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top